文献速递泌尿男性生殖肿瘤支持与姑息治疗

NECTIN4扩增在实体瘤中常见并可预测转移性尿路上皮癌对恩诺单抗维多汀的应答

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
PubMed 文献 · J Clin Oncol · 2024-04-24

该多中心研究采用NECTIN4特异性FISH检测,在108例接受恩诺单抗维多汀(EV)治疗的转移性尿路上皮癌(mUC)患者中评估NECTIN4拷贝数变异的预测价值,并分析103例未接受EV治疗患者的预后价值及TCGA泛癌数据。结果显示NECTIN4扩增与EV客观应答和生存获益相关,且在乳腺癌和肺癌等中也较常见。

要点

  • NECTIN4扩增在mUC中约占26%,在肌层浸润性膀胱癌TCGA数据中约占17%。
  • NECTIN4扩增患者EV客观应答率96%(27/28),非扩增者为32%(24/74),P<.001。
  • 校正年龄、性别和Bellmunt风险因素后,NECTIN4扩增与死亡风险降低92%相关(HR 0.08,95%CI 0.02-0.34,P<.001)。

核心结论

  • NECTIN4扩增是mUC患者EV应答和长期生存的基因组预测因子。

研究设计与样本

  • 多中心EV治疗的mUC患者队列(mUC-EV,n=108),采用NECTIN4特异性FISH检测拷贝数变异并与蛋白表达、疗效和结局关联。
  • 另评估非EV治疗的mUC转移灶活检队列(mUC-non-EV,n=103)的预后价值,并查询TCGA数据集(32种癌症类型,10712例)的NECTIN4拷贝数变异。

主要发现

  • NECTIN4扩增是肌层浸润性膀胱癌(TCGA膀胱癌数据集约17%)和mUC(本mUC队列约26%)中的常见基因组事件。
  • 在mUC-EV中,NECTIN4扩增是转移进展过程中的稳定基因组改变,并与膜NECTIN4蛋白表达增强相关。
  • NECTIN4扩增患者EV客观应答率为96%(27/28),非扩增亚组为32%(24/74),P<.001。
  • 校正年龄、性别和Bellmunt风险因素后,NECTIN4扩增使死亡风险降低92%(HR 0.08,95%CI 0.02-0.34,P<.001)。
  • 在mUC-non-EV中,NECTIN4扩增与结局无关;TCGA泛癌分析显示NECTIN4扩增在其他癌症中也常见,如乳腺癌和肺癌中为5%-10%。

关键数值与推荐

  • NECTIN4扩增患者EV客观应答率为96%(27/28),非扩增亚组为32%(24/74)。
  • 校正后NECTIN4扩增与死亡风险降低92%相关(HR 0.08,95%CI 0.02-0.34,P<.001)。
  • TCGA膀胱癌数据集中NECTIN4扩增约17%,本mUC队列约26%。
  • TCGA泛癌分析中乳腺癌和肺癌的NECTIN4扩增为5%-10%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS: We established a NECTIN4-specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108). CNVs were correlated with membranous NECTIN4 protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of NECTIN4 CNVs measured in metastatic biopsies of non-EV-treated mUC (mUC-non-EV, n = 103). Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712 patients across 32 cancer types) for NECTIN4 CNVs. RESULTS: NECTIN4 amplifications are frequent genomic events in muscle-invasive bladder cancer (TCGA bladder cancer data set: approximately 17%) and mUC (approximately 26% in our mUC cohorts). In mUC-EV, NECTIN4 amplification represents a stable genomic alteration during metastatic progression and associates with enhanced membranous NECTIN4 protein expression. Ninety-six percent (27 of 28) of patients with NECTIN4 amplifications demonstrated objective responses to EV compared with 32% (24 of 74) in the nonamplified subgroup (P < .001). In multivariable Cox analysis adjusted for age, sex, and Bellmunt risk factors, NECTIN4 amplifications led to a 92% risk reduction for death (hazard ratio, 0.08 [95% CI, 0.02 to 0.34]; P < .001). In the mUC-non-EV, NECTIN4 amplifications were not associated with outcomes. TCGA Pan-Cancer analysis demonstrated that NECTIN4 amplifications occur frequently in other cancers, for example, in 5%-10% of breast and lung cancers. CONCLUSION: NECTIN4 amplifications are genomic predictors of EV responses and long-term survival in patients with mUC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Klümper N, Tran NK, Zschäbitz S, et al. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J Clin Oncol. 2024. PMID: 38657187. doi:10.1200/JCO.23.01983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。